The test, called the High-risk Influenza Screen Test, analyzes genetic codes immune cells release into the blood to warn of a potentially deadly infection caused by the flu virus, such as pneumonia.
The test needs one drop of a patient’s blood to predict if the patient is at-risk of developing a secondary infection. The test has a 91 percent accuracy rate, according to the research team.
The test can also be used to track the efficacy of new drugs as it measures a patient’s immune response.
The researchers detailed their findings in the European Respiratory Journal.
More articles on quality:
Depression affects nearly one-third of hospital patients, study finds
AHA urges CMS: Use only quality measures that matter
61% of pediatric nurses in poor work environments miss care, study shows
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.